VERAXA Secarna AOC Research Milestone
Analysis based on 7 articles · First reported Aug 24, 2026 · Last updated Aug 27, 2026
The positive in vitro proof-of-concept validates VERAXA's conjugation platform and may enhance investor confidence in its partnering strategy, potentially supporting its stock price. For Secarna, the milestone strengthens its AOC development prospects, though as a private company the direct market impact is limited.
VERAXA Biotech AG AG (NASDAQ: VRXA) and Secarna Pharmaceuticals GmbH & Co. KG announced on August 24, 2026, that they achieved a research milestone in their strategic collaboration to develop antibody-oligonucleotide conjugates (AOCs) for autoimmune and chronic immune diseases. In early in vitro studies, an AOC candidate combining both companies' technologies demonstrated greater potency than the equivalent unconjugated oligonucleotide. The companies are now discussing next steps in the alliance. This milestone validates VERAXA's conjugation technology and click chemistry platform beyond its primary oncology focus, while Secarna contributes its OligoCreator platform and oligonucleotide expertise. The collaboration was originally announced in September 2025.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard